Galera Therapeutics Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Galera Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Galera Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Galera Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 4.3 M |
Galera |
Galera Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Galera Therapeutics on December 22, 2024 and sell it today you would earn a total of 100.00 from holding Galera Therapeutics or generate -100.0% return on investment over 90 days. Galera Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Galera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galera Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galera Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Galera Therapeutics, and traders can use it to determine the average amount a Galera Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GRTX |
Based on monthly moving average Galera Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galera Therapeutics by adding Galera Therapeutics to a well-diversified portfolio.
Galera Therapeutics Fundamentals Growth
Galera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Galera Therapeutics, and Galera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galera Pink Sheet performance.
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) | ||||
| Cash And Equivalents | 52.01 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 152.3 M | ||||
| Debt To Equity | 0.09 % | ||||
| Book Value Per Share | (2.48) X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Earnings Per Share | (0.91) X | ||||
| Total Asset | 26.14 M | ||||
| Retained Earnings | (437.41 M) | ||||
| Current Asset | 36.65 M | ||||
| Current Liabilities | 5.37 M | ||||
Things to note about Galera Therapeutics performance evaluation
Checking the ongoing alerts about Galera Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Galera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galera Therapeutics is not yet fully synchronised with the market data | |
| Galera Therapeutics has some characteristics of a very speculative penny stock | |
| Galera Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (59.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galera Therapeutics currently holds about 52.01 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94. | |
| Roughly 36.0% of the company shares are held by company insiders |
- Analyzing Galera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galera Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Galera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galera Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galera Therapeutics' pink sheet. These opinions can provide insight into Galera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |